ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study

• Published in: Journal of cancer research and clinical oncology Vol. 145; no. 3; pp. 765 - 774
• Main Authors: Iivanainen, Sanna, Alanko, Tuomo, Peltola, Katriina, Konkola, Teemu, Ekström, Jussi, Virtanen, Henri, Koivunen, Jussi P.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2019; Springer Nature B.V
• Subjects: Adult; Aged; Antineoplastic Agents, Immunological - adverse effects; Appetite loss; Cancer; Cancer Research; Chemotherapy; Clinical trials; Correlation analysis; Cough; Data processing; Electronic Health Records; Female; Hematology; Humans; Immune checkpoint inhibitors; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Nausea; Neoplasms - drug therapy; Oncology; Original Article – Clinical Oncology; Original – Clinical Oncology; Pain; Patient Reported Outcome Measures; Patients; Pruritus; Quality of life; Questionnaires; Retrospective Studies; Stomach; Surveys and Questionnaires; Vomiting; Patient-reported outcomes; Immune checkpoint inhibitor therapy; Symptoms; Real-world data
• ISSN: 0171-5216; 1432-1335
• DOI: 10.1007/s00432-018-02835-6

Purpose Patient-reported outcome (PRO) follow-up has been shown to improve quality of life (QoL) and survival of cancer patients receiving chemotherapy. Kaiku Health application is a web-based electronic PRO (ePRO) tool which is designed for follow-up of cancer patients receiving immune checkpoint inhibitors (ICI). Purpose of the current study is to investigate whether symptoms collected by Kaiku Health ePRO tool on cancer patients receiving immune checkpoint inhibitors (ICI) follows to symptoms reported in clinical trials and whether coupling of specific symptoms does occur. Methods We retrospectively collected data on symptom timing and severity, and QoL of patients followed with Kaiku Health IO module in two Finnish cancer centers between 2017 and 2018. Kaiku Health IO module consists of 18 adaptive questions, which assess the presence and severity of symptoms. Patients were requested (via e-mail) to fill online symptom questionnaires with 3–7 day interval and QoL questionnaires (QLQ-C30) with 1–2 month interval. Results The IO module was used to follow 37 patients who had filled in total 559 symptom questionnaires. There was good adherence to ePRO follow-up with a median of 11 questionnaires filled per patient. The reported symptoms and their severity follow closely what has been seen in clinical trials investigating ICIs. Correlation analysis of the symptoms showed the strongest positive correlations between itching and rash; nausea and vomiting, decreased appetite, or stomach pain; cough and shortness of breath. Conclusions The results of the current study suggest that real-world symptom data collected through the ePRO application on cancer patients receiving ICI therapy aligns with the data from clinical trials. Correlations between different symptoms occur, which might reflect therapeutic efficiency, side effects, or tumor progression. These correlations should be further investigated with data coupled to clinical outcomes.